Dr. Reddy's is acquiring Haleon’s global portfolio of consumer healthcare brands in the nicotine replacement therapy outside US for £500M ($633M). The transaction is expected to complete in 4Q24.
What is covered in the Full Insight:
Introduction to Dr. Reddy's Laboratories and the Acquisition
Details of the Acquisition Agreement
Benefits and Strategic Importance of the Acquisition
Financial Implications and Market Impact
Conclusion and Forward Looking Statements
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.